Evaluation of the chemical contamination related to the manual cytotoxic production in an isolator and a new robotic drug preparation system (Kiro Oncology®)

M. Ayadi , M. Jobard, C. Cros, M-L. Brandely-Piat, R. Batista Service de Pharmacie Clinique, Groupe des Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, 1 place du Parvis Notre Dame, 75004 Paris, France

Our hospital pharmacy has two isolators and one robot (Kiro Oncology®, Kirogrifols) for the preparation of intravenous chemotherapy drugs. The aim of this study was to compare the chemical contamination generated during drug compounding using manual and robotic procedures with fluorescein.

To simulate the preparation process, fluorescein powder vials were used instead of cytotoxic drug vials. Two sets of eight preparations (bags, syringes, elastomeric pumps) were performed with 100 or 500 mg fluorescein powder vials filled with 10 or 50 ml of water for injection. Each set was repeated 3 times at 3 different days for both procedures. Manual production was performed by different operators for each set. At the end of each set, the contamination was assessed by visual inspection with UV light. In case of contamination, the area was photographed to evaluate the number and the diameter of fluorescein droplets.

For manual production, droplets were found on gloves (4 sets/6), sterile fields (4/6) and waste containers (2/6). The packaging of end products was contaminated for 16 of the 48 preparations (33%). For robot-assisted production, droplets were found on one glove (1 set/6), one syringe end-product (1/6), the working area (1/6), the waste containers (1/6) and the spikes for the filling of the vials (6/6). No packaging of end product was contaminated. Two high contaminations (2/6) of the working area (from 19 to 168 droplets) were observed. They were due to robot failures (incorrect injection in the final container).

In manual process, contamination depends on the experience of the operators. The robot-assisted production allows to reduce outside contamination of the preparations (0 contaminated packaging vs 16 and only one end product contaminated of 48 preparations). However, potential exposure of the operators due to robot failures remains a weak point requiring the implementation of adapted procedures to avoid this risk.

Discussion forum

GERPAC provides for its members a discussion forum specifically devoted to technology in hospital pharmacy

Access forum

GERPAC
Association Loi 1901
Siège social : Chez Jean-Yves Jomier / 8ter rue Léon Bussat, 64000 PAU
Immatriculation formation N° 72 64 035 30 64
Contact us Legal notes - Management of personal data